Insider trading

Period: 120 months Stock: WVE Minimum amount: $100K × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

68 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

68 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

68 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

68 decisions over 120 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
68 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
68 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

68 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
30 Mar 2026
RA CAPITAL MANAGEMENT, L.P. Director · indirect
Bought
$6.31M 971,091 at 6.50
3.7%
27 Mar 2026
RA CAPITAL MANAGEMENT, L.P. Director · indirect
Bought
$16.05M 2,495,623 at 6.43
10.6%
26 Mar 2026
RA CAPITAL MANAGEMENT, L.P. Director · indirect
Bought 2×
$32.27M 5,305,782 at 6.08
29.1%
Largest buy in 3 yrs
26 Feb 2026
Francis Chris See Remarks
Sold on a plan 2×
$499.59K 33,194 at 15.05
34.9%
Planned (10b5-1)
9 Feb 2026
BOLNO PAUL President and CEO
Sold at will
$140.96K 10,480 at 13.45
3.7%
Not planned
2 Jan 2026
Francis Chris See Remarks
Sold on a plan 2×
$150.26K 9,375 at 16.03
27.3%
Planned (10b5-1)
11 Dec 2025
GSK plc 10% owner · indirect
Bought
$27.93M 1,470,000 at 19.00
8.8%
Largest buy in 3 yrs
9 Dec 2025
Moran Kyle Chief Financial Officer
Sold on a plan 2×
$1.00M 50,036 at 20.03
35.9%
Planned (10b5-1)
8 Dec 2025
Francis Chris See Remarks
Sold on a plan 9×
$6.43M 441,031 at 14.57
94.6%
Sold half or more
8 Dec 2025
Moran Kyle Chief Financial Officer
Sold on a plan 4×
$3.10M 210,000 at 14.77
70.2%
Sold half or more
8 Dec 2025
Tan Aik Na Director
Sold on a plan 8×
$1.82M 134,218 at 13.58
84.1%
Sold half or more
8 Dec 2025
Sold on a plan 4×
$1.37M 93,445 at 14.65
88.0%
Sold half or more
8 Dec 2025
Rawcliffe Adrian Director
Sold on a plan
$630.00K 42,000 at 15.00
76.8%
Sold half or more
8 Dec 2025
Sold on a plan 2×
$269.46K 20,000 at 13.47
6.8%
Planned (10b5-1)
8 Dec 2025
CORRIGAN MARK Director
Sold on a plan 2×
$217.30K 16,115 at 13.48
35.9%
Planned (10b5-1)
8 Dec 2025
Wagner Heidi L Director
Sold on a plan 2×
$189.00K 14,000 at 13.50
23.8%
Planned (10b5-1)
13 Nov 2025
Rawcliffe Adrian Director
Sold on a plan
$109.42K 16,115 at 6.79
55.9%
Sold half or more
22 Aug 2025
BOLNO PAUL President and CEO
Sold on a plan
$2.19M 217,351 at 10.10
64.2%
Sold half or more
22 Aug 2025
Sold on a plan
$100.00K 10,000 at 10.00
3.4%
Planned (10b5-1)
15 Aug 2025
Tan Aik Na Director
Sold on a plan
$194.25K 21,000 at 9.25
34.2%
Planned (10b5-1)
13 Jun 2025
Sold on a plan
$208.50K 30,000 at 6.95
9.6%
Planned (10b5-1)
20 Mar 2025
Sold on a plan
$102.57K 10,500 at 9.77
39.5%
Planned (10b5-1)
7 Mar 2025
BOLNO PAUL President and CEO
Sold on a plan
$1.62M 169,025 at 9.57
33.3%
Planned (10b5-1)
25 Nov 2024
BOLNO PAUL President and CEO
Sold on a plan
$750.00K 50,000 at 15.00
18.7%
Planned (10b5-1)
15 Nov 2024
BOLNO PAUL President and CEO
Sold on a plan
$733.67K 51,234 at 14.32
19.1%
Planned (10b5-1)
8 Nov 2024
Francis Chris See Remarks
Sold on a plan
$576.00K 36,000 at 16.00
100%
Sold half or more
16 Oct 2024
Francis Chris See Remarks
Sold on a plan 4×
$2.86M 208,836 at 13.67
100%
Sold half or more
16 Oct 2024
BOLNO PAUL President and CEO
Sold on a plan
$1.36M 90,474 at 15.00
25.2%
Planned (10b5-1)
27 Sep 2024
GSK plc 10% owner · indirect
Bought
$22.34M 2,791,930 at 8.00
20.0%
Largest buy in 3 yrs
25 Sep 2024
Moran Kyle Chief Financial Officer
Sold on a plan
$154.31K 17,146 at 9.00
46.4%
Planned (10b5-1)
21 Aug 2024
BOLNO PAUL President and CEO
Sold on a plan
$279.56K 48,366 at 5.78
11.9%
Planned (10b5-1)
11 Dec 2023
RA CAPITAL MANAGEMENT, L.P. Director · indirect
Bought
$5.00M 1,000,000 at 5.00
5.5%
7 Dec 2023
GSK plc 10% owner · indirect
Bought
$16.50M 3,300,000 at 5.00
30.9%
First buy on file
23 Aug 2023
Moran Kyle Chief Financial Officer
Sold on a plan
$176.12K 37,062 at 4.75
44.6%
Planned (10b5-1)
16 Feb 2023
BOLNO PAUL President and CEO
Sold, plan not stated
$118.78K 29,400 at 4.04
6.7%
16 Jun 2022
RA CAPITAL MANAGEMENT, L.P. Director · indirect
Bought
$20.38M 9,480,052 at 2.15
123%
First buy on file
16 Feb 2021
BOLNO PAUL President and CEO
Sold, plan not stated
$118.44K 11,205 at 10.57
2.7%
15 Sep 2020
BOLNO PAUL President and CEO
Sold, plan not stated
$1.50M 100,000 at 15.00
26.9%
25 Aug 2020
BOLNO PAUL President and CEO
Sold, plan not stated
$300.00K 25,000 at 12.00
8.4%
2 Jul 2020
BOLNO PAUL President and CEO
Sold, plan not stated 4×
$1.52M 147,577 at 10.30
35.2%
3 Dec 2019
Vargeese Chandra Senior VP, Drug Discovery
Sold, plan not stated
$210.00K 6,000 at 35.00
13.0%
20 Nov 2019
Sold, plan not stated 3×
$920.21K 30,039 at 30.63
50.0%
Sold half or more
15 Mar 2019
BOLNO PAUL President and CEO
Sold, plan not stated 4×
$2.27M 50,000 at 45.48
13.1%
11 Mar 2019
Panzara Michael A. Franchise Lead, Neurology
Sold, plan not stated
$336.00K 7,000 at 48.00
13.4%
19 Feb 2019
BOLNO PAUL President and CEO
Sold, plan not stated 2×
$281.46K 7,733 at 36.40
2.8%
24 Jan 2019
RA CAPITAL MANAGEMENT, L.P. Director · indirect
Bought
$10.00M 263,158 at 38.00
3.5%
First buy on file
14 Nov 2018
Sold, plan not stated 2×
$582.85K 15,000 at 38.86
20.0%
25 Sep 2018
Francis Chris See Remarks
Sold, plan not stated
$590.41K 10,543 at 56.00
32.3%
24 Sep 2018
Regnante Keith Chief Financial Officer
Sold, plan not stated
$1.62M 29,500 at 55.00
63.5%
Sold half or more
24 Sep 2018
Vargeese Chandra Senior VP, Drug Discovery
Sold, plan not stated
$165.00K 3,000 at 55.00
9.9%
Showing 1–50 of 68. Page 1 of 2 Older →